MITRA-FR: Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Courtesy of Dr. Adolfo Ferrero.

INTRODUCCION: In patients with chronic heart failure and reduced left ventricular ejection fraction, severe secondary mitral valve regurgitation is associated with bad prognosis. Whether percutaneous mitral valve repair improves clinical results in this patient population, remains unclear, despite prior multicenter studies supporting this view.

METHODS: Patients with severe secondary mitral valve regurgitation (defined as an effective regurgitant orifice area of >20 mm2 or a regurgitant volume of >30 ml per beat), left ventricular ejection fraction between 15 and 40%, and symptomatic heart failure, were randomized 1:1 to percutaneous mitral-valve repair in addition to medical therapy (intervention group; 152 patients) vs. medical therapy alone (control group; 152 patients). Primary efficacy end point was a composite of all cause death or unplanned hospitalization for heart failure at 12 months.

 

RESULTS: At 12 months, primary end point was 54.6% (83 of 152 patients) in the intervention group and 51.3% (78 of 152 patients) in the control group (OR 1.16; 95% CI, 0.73 to 1.84; P=0.53). All cause death was 24.3% (37 of 152 patients) in the intervention group and 22.4% (34 of 152 patients) in the control group (HR 1.11; 95% CI, 0.69 to 1.77). Unplanned hospitalization for heart failure was 48.7% (74 of 152 patients) in the intervention group and 47.4% (72 of 152 patients) in the control group (HR 1.13; 95% CI, 0.81 to 1.56).


Read also: Antiaggregation Time after Treating Bifurcations.


CONCLUSIONS: Among patients with severe secondary mitral regurgitation, death or unplanned hospitalization rates for heart failure at 1 year did not differ significantly between patients undergoing percutaneous mitral-valve repair and medical therapy, and those who received medical therapy alone.

 

Courtesy of Dr. Adolfo Ferrero.

 

Original title: Percutaneous Repair or Medical Treatmentfor Secondary Mitral Regurgitation.

Reference: J.-F. Obadia, Et Al. For the MITRA-FR Investigators. NEJM DOI: 10.1056/NEJMoa1805374.

MITRA-FR: Reparación percutánea o tratamiento médico para la insuficiencia mitral secundaria

MITRA-FR


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...